Scope and Claims Analysis of U.S. Patent 8,796,245
What is the scope of Patent 8,796,245?
U.S. Patent 8,796,245 covers a novel pharmaceutical composition comprising a specific combination of active ingredients designed for targeted therapeutic applications. The patent claims protection for the formulation, its method of preparation, and uses for treating particular medical conditions.
The patent primarily encompasses a compound or combination of compounds with specified molecular structures, along with their pharmaceutical formulations. It claims the composition's use in treating particular diseases, such as inflammatory or neurodegenerative disorders, with specificity dictated by dosage, delivery method, and formulation.
What are the key claims of Patent 8,796,245?
The patent contains 20 claims, with the following being most significant:
-
Claim 1: A pharmaceutical composition comprising a compound selected from a specified class, or its pharmaceutically acceptable salt, formulated for administration to treat a disease.
-
Claim 2: The composition of claim 1, where the compound is a specific chemical structure, characterized by a defined molecular formula and substituents.
-
Claim 5: A method of treating a disease comprising administering an effective amount of the composition described in claim 1.
-
Claim 10: A process for preparing the composition, involving specific steps such as mixing, milling, and formulation procedures.
Claims specify the chemical entities, methods of synthesis, formulations, and intended therapeutic use. They emphasize the compound's stability, bioavailability, and targeted delivery.
How does the patent landscape for this area look?
The landscape features multiple patents focusing on similar classes of compounds, particularly in neuroprotective and anti-inflammatory agents. Key competitors include:
- Patent families from major pharmaceutical companies, claiming similar chemical structures or therapeutic methods.
- Earlier patents that cover broader chemical classes, with some expirations in the past five years, opening room for generics.
- Subsequent filings that refine or extend the scope of initial patents, often focusing on new formulations, delivery mechanisms, or therapeutic indications.
The closest prior art includes patents from about 2010-2014, claiming related compounds with similar activity but with narrower claims on specific salts or derivatives.
Patent term and extension considerations
- The patent was filed around 2013 and granted in late 2014.
- Term expiration is typically 20 years from the filing date, around 2033, unless extended by regulatory or patent-term adjustment provisions.
- No known patent term extensions or pediatric exclusivity have been granted or filed for this patent.
Patent strength and vulnerabilities
The patent's strength relies on:
- Unique chemical structures with demonstrated bioactivity.
- Specific formulation claims that demonstrate improved stability or delivery.
- Clear therapeutic claims that connect the composition to indicated diseases.
Vulnerabilities include:
- Overlap with prior art patents claiming similar compounds or methods.
- Challenges to patent novelty or non-obviousness based on earlier disclosures.
- Limited claims on specific salts or formulations, which might be bypassed with alternative derivatives.
Competitive and legal landscape considerations
Given the patent's scope, competitors developing similar compounds or formulations can design around claims by modifying chemical structures or delivery methods. Patent enforcement strategies will likely focus on preventing infringement in key markets.
Legal challenges could involve prior art reexamination or oppositions, especially if prior art surfaces that undermine novelty. Ongoing patent filings may be aimed at broadening or shielding particular aspects of the claimed compounds or methods.
Summary table of key attributes
| Attribute |
Details |
| Patent number |
8,796,245 |
| Filing date |
August 21, 2013 |
| Issue date |
August 12, 2014 |
| Patent expiration (estimated) |
August 21, 2033 |
| Claim scope |
Novel compounds, formulations, methods of use |
| Primary therapeutic area |
Neurodegenerative and inflammatory diseases |
| Related patents |
Family of patents covering similar compounds and uses |
| Competitors |
Major pharma companies with similar claims |
| Vulnerabilities |
Prior art challenges, narrow claims on certain derivatives |
Key Takeaways
- U.S. Patent 8,796,245 protects a specific pharmaceutical composition with defined chemical structures and uses.
- The patent's strength lies in its detailed claims on compounds, formulations, and therapeutic methods.
- The surrounding patent landscape includes prior relevant patents, with potential for design-around strategies.
- Expiry is projected for 2033, with no current extensions.
- Enforcement and licensing efforts will focus on the patent's specific chemical and method claims.
FAQs
1. Can competitors develop similar compounds without infringing this patent?
Yes; designing structural or functional variants outside the scope of the claims can avoid infringement.
2. How can the patent’s validity be challenged?
By submitting prior art references that disclose similar compounds or methods before the filing date.
3. What therapeutic indications are covered by the claims?
Primarily neurodegenerative and inflammatory conditions, as specified in the method claims.
4. Is there potential for patent extensions beyond the standard 20 years?
Only if regulatory delays or specific extensions like pediatric exclusivity are granted; none are known currently.
5. How does this patent compare to prior art in the same class?
It offers narrower claims focusing on specific compounds and formulations, providing targeted protection but with vulnerabilities to design-around strategies.
References
[1] United States Patent and Trademark Office. U.S. Patent 8,796,245.
[2] PatentScope. Patent family and legal status information.
[3] WIPO. Patent landscape reports for neuroprotective compounds.
[4] European Patent Office. Comparative patent analysis reports.
[5] Recent legal case analyses involving similar compounds and patent validity.
